1.
|
Re-election of each of (a) Ms. Sarit Firon, (b) Mr. Martin S. Gerstel, (c) Mr. Ziv Kop, (d) Dr. Adrian Percy, (e) Mr. Leon Y. Recanati and (f) Dr. Oded Shoseyov for a one-year term as a
director of the Company, until the Company’s annual general meeting of shareholders in 2021 and until his or her successor is duly elected and qualified.
|
2.
|
Ratification and approval of past and future annual option grants to each of the Chairman of the board of directors of the Company, or the Board, Mr. Martin S. Gerstel, and the director,
Mr. Leon Y. Recanati (in the case of future option grants, subject to their reelection as directors pursuant to Proposal 1(b) and 1(e), respectively).
|
3.
|
Approval of the grant of options to purchase 500,000 of the Company’s ordinary shares to the Company’s President & Chief Executive Officer, Mr. Ofer Haviv.
|
4.
|
Approval and ratification of the Company’s procuring coverage, and the Company’s payment of premiums and deductibles, consistent with market terms and not material to the Company, under its
renewed director and officer liability, or D&O, insurance policies.
|
5.
|
Approval of an amendment to the Company’s Officers Compensation Policy that inserts detail as to the maximum coverage levels under the Company’s D&O insurance policies and requires that
premiums and deductibles paid by the Company under its D&O insurance policies be consistent with market terms and not material to the Company.
|
6.
|
Approval of the re-appointment of Kost Forer Gabbay & Kasierer, registered public accounting firm, a member firm of Ernst & Young Global, as the Company’s independent registered
public accounting firm for the year ending December 31, 2020 and until the Company’s next annual general meeting of shareholders, and the authorization of the Board or the audit committee thereof to fix such accounting firm’s annual
compensation.
|
Date: October 20, 2020 |
EVOGENE LTD.
(Registrant) By: /s/ Dorit Kreiner —————————————— Dorit Kreiner Chief Financial Officer |